****

**ACCREDITATION**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**TARGET AUDIENCE**

Attending physicians, House staff, Fellows, Medical Students, Nurses, PA’s

**NEEDS ASSESSMENT**

SGLT2 inhibitors have been demonstrated to improve renal outcomes in patients with T2DM. Although originally thought to be in the realm of endocrinologists, nephrologists will soon need to become comfortable prescribing these medications as well.

**LEARNING OBJECTIVES**

At the conclusion of this activity, participants will be able to:

1. Understand the impact of SGLT2 inhibitors on kidney outcomes in T2DM patients.
2. Describe dosing strategies for commonly prescribed SGLT2 inhibitors.
3. Anticipate and treat side effects of SGLT2 inhibitors

**DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY DISCLOSURES**

Silvio Inzucchi, M.D.

AstraZeneca – Consultant Trial Executive Committee Member

Boehringer Ingelheim – Lecture, Trial Publications Committee Member

Novo Nordisk – Consultant

Merck - Lecture

Abbott/Alere - Consultant

Sanofi/Lexicon – Trial Steering Committee Member

Ethan Marin, M.D., Ph.D. – None

**“SGLT2 Inhibitors and the Nephrologist”**

Silvio Inzucchi, MD

*Professor of Medicine (Endocrinology)*

**Friday, February 28, 2020**

**12:00 PM – 1:00 PM**

**The Anlyan Center – TAC N203**

Course Director/Host: Ethan Marin, M.D., Ph.D.

*There is no corporate support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.*

Yale School of Medicine

Department of Internal Medicine

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

NEPHROLOGY

Regularly Scheduled Series